Given that you clicked on this article, it seems safe to assume you either own stock in SVB Financial (NASDAQ: SIVB ) or are considering buying shares in the near future. If so, then you've come to the right place. The table below reveals the nine most critical numbers that investors need to know about SVB Financial stock before deciding whether to buy, sell, or hold it.
SVB Financial is not your typical bank. Located in Northern California, it's the holding company for Silicon Valley Bank, a niche lender that focuses almost exclusively on companies in the technology, life sciences, and winery space. Think venture capital. "For nearly three decades," its website reads, "SVB Financial Group and its subsidiaries, including Silicon Valley Bank, have been dedicated to helping entrepreneurs succeed." And if its share-price performance is any indication, this model has succeeded. Over the past 10 years, the total return to shareholders has been 273%. For context, only a handful of banks exceeded the 100% mark over this same time period -- including JPMorgan Chase, Goldman Sachs, Wells Fargo, and PNC Financial -- and roughly half of the 100-plus banks I examined actually declined in value over the same time period.
Best Life Sciences Companies To Own For 2014: U S Concrete Inc.(USCR)
U.S. Concrete, Inc. engages in the production and sale of ready-mixed concrete, precast concrete products, and concrete-related products for use in commercial, residential, and public works construction projects in the United States. It operates in two segments, Ready-Mixed Concrete and Concrete-Related Products, and Precast Concrete Products. The Ready-Mixed Concrete and Concrete-Related Products segment involves in the formulation, preparation, and delivery of ready-mixed concrete to customers? job sites; and the provision of various services that include the formulation of mixtures for specific design uses, on-site and lab-based product quality control, and customized delivery programs. This segment also engages in the mining and sale of aggregates, such as crushed stone aggregates, sand, and gravel; and the resale of building materials, including rebars, concrete blocks, wire mesh, color additives, curing compounds, grouts, wooden forms, concrete masonry, and tools. Th e Precast Concrete Products segment produces a range of precast concrete products for use in various architectural applications, including free-standing walls used for landscaping; soundproofing and security walls; panels used to clad a building facade; and storm water drainages. This segment also offers various finished products consisting of utility vaults, manholes, catch basins, highway barriers, curb inlets, pre-stressed bridge girders, concrete piles, and custom-designed architectural products. The company serves general contractors, concrete sub-contractors, design engineers, architects, governmental agencies, property owners and developers, and home builders principally in Texas, California, New Jersey, and New York. As of March 7, 2011, it had 102 fixed and 11 portable ready-mixed concrete plants, 7 precast concrete plants, and 7 aggregates facilities. U.S. Concrete, Inc. was founded in 1948 and is based in Houston, Texas.
Advisors' Opinion:- [By cnAnalyst]
US Concrete Inc (NASDAQ:USCR) is the 9th best-performing stock last month in this segment of the market. It was up 65.22% for the past month. Its price percentage change was -79.12% year-to-date.
Best Life Sciences Companies To Own For 2014: British Sky Broadcasting(BSY.L)
British Sky Broadcasting Group plc, through its subsidiaries, provides pay television services in the United Kingdom and the Republic of Ireland. It retails owned and third parties? channels; and the Sky Box Office service, which include a pay-per-view service offering movies, sporting events, and concerts to direct-to-home (DTH) customers. The company owns, operates, distributes, and retails 30 Sky Channels through its DTH service, and approximately 50 high definition TV (HD) channels; retails 147 Sky Distributed Channels to its DTH customers; and operates radio and free to air HD channels. As of September 30, 2011, it offered television services to 10,213,000 customers. It also provides broadband and telephony services. In addition, the company offers a range of channel packages that provide a selection of sports, news, music, and entertainment services to pubs and clubs, hotels, offices, retail outlets, and betting premises; and offers various advertising solutions, in cluding traditional ads, sponsorship, online, and video-on-demand, as well as text and interactive advertising to pubs, train stations, and on mobile. Further, it provides a range of betting and gaming services through the Internet, phone, and interactive TV, including Sky Bet, Sky Poker, Sky Vegas, and Sky Bingo; operates a portfolio of online sports media brands; and provides sponsorship and advertising for channels. Additionally, the company designs, develops, and manufactures set top boxes. British Sky Broadcasting Group plc was incorporated in 1988 and is headquartered in Isleworth, the United Kingdom.
5 Best China Stocks To Buy For 2014: Atlas Pipeline Partners L.P.(APL)
Atlas Pipeline Partners, L.P. engages in gathering and processing natural gas in the Mid-Continent and Appalachia regions; and transporting natural gas liquids (NGL) in the Mid-Continent region. The company owns and operates approximately 9,100 miles of intrastate natural gas gathering systems located in Oklahoma, Kansas, Texas, and Tennessee that gather gas from wells and central delivery points, and deliver natural gas to the company?s natural gas processing plants, as well as to the third-party pipelines; approximately 100 miles of active natural gas gathering systems located in Tennessee; and 7 natural gas processing plants with an aggregate capacity of approximately 610 million cubic feet per day in Oklahoma and Texas. It provides natural gas gathering and processing services in the Permian, Anadarko, and Appalachian Basins. The company also owns approximately 2,200 mile common-carrier pipeline system that transports NGLs from New Mexico and Texas to Mont Belvieu, Te xas. Atlas Pipeline Partners, L.P. was founded in 1999 and is based in Moon Township, Pennsylvania.
Advisors' Opinion:- [By Skousen]
The company's secret is that it doesn't drill for a drop of oil and it doesn't frack a single foot of shale gas. What it does is keep companies who do at its mercy.
Atlas Pipeline Partners (APL:nyse) owns 1,600 miles of pipeline connected to nearly 6,000 wells and is adding over 800 new wells per year in Appalachia. It also operates a growing interstate pipeline system in the Fayetteville Shale. Plus, it has a great deal with one of the most active drillers in America: Atlas Energy. Every well that Atlas Energy drills has to be connected to Atlas Pipeline's system. These are low-risk assets. Now let's talk dividend. Since 2000, APL's average dividend increase clocked in at 7 cents a year. A plump year offered a 107% increase. While it's true that 2008 was a tough year for natural gas, NGLs (APL's primary product) are up 50% from their December lows. Aside from price recovery, there's another catalyst for dividend growth. Given the prime location of its pipelines in Appalachia, you have every reason to expect an increased dividend payout down the road.
War horse Leon Cooperman, shares my interest in APL. He is one of the great living investors. At a recent Manhattan value investors' conference, Cooperman confessed, "This is the most difficult environment I've lived through. And I've been doing this for 41 years." But when he got to talking about getting 20%-plus on your money with APL, he had this to say: "At my age, it's better than sex, but that's just me."
Best Life Sciences Companies To Own For 2014: Perma-Fix Environmental Services Inc.(PESI)
Perma-Fix Environmental Services, Inc., through its subsidiaries, operates as an environmental and technology know-how company in the United States. It operates in two segments, Treatment and Services. The Treatment segment provides nuclear, low-level radioactive, mixed waste containing hazardous and low-level radioactive constituents, and hazardous and non-hazardous waste treatment, processing, and disposal services primarily through four licensed and permitted treatment and storage facilities. It also engages in the research and development activities to identify, develop, and implement waste processing techniques for problematic waste streams. The Services segment offers on-site waste management services to commercial and government customers; and operates an equipment calibration and maintenance laboratory that services, maintains, and calibrates health physics and industrial hygiene instrumentation. It also provides technical services, which include health physic and radiological control technician services; safety and industrial hygiene services; and staff augmentation services, such as consulting, engineering, project management, waste management, environmental, and decontamination and decommissioning field personnel, technical personnel, and management and services. In addition, this segment offers consulting engineering services, including consulting environmental services comprising air, water, and hazardous waste permitting; air, soil, and water sampling; compliance reporting; emission reduction strategies; compliance auditing; and various compliance and training activities. The company serves research institutions, commercial companies, and public utilities, as well as governmental agencies through direct sales and intermediaries. Perma-Fix Environmental Services, Inc. was founded in 1990 and is based in Atlanta, Georgia.
Best Life Sciences Companies To Own For 2014: Sarepta Therapeutics Inc (SRPT)
Sarepta Therapeutics Inc., formerly AVI BioPharma, Inc., incorporated on July 22, 1980, biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of rare and infectious diseases. The Company�� product candidates include Eteplirsen, AVI-6002, AVI-6003, and AVI-7100. As of December 31, 2011, the Company primarily focused on advancing the development of its Duchenne muscular dystrophy drug candidates, including its lead product candidate, eteplirsen, which is in a Phase IIb trial. The Company is also focused on developing therapeutics for the treatment of infectious diseases, including its lead infectious disease programs aimed at the development of drug candidates for the Ebola and Marburg hemorrhagic fever viruses. The Company's program focuses on the development of disease-modifying therapeutic candidates for Duchenne muscular dystrophy (DMD). The Company initiated a Phase IIb trial for eteplirsen in August 2011 with an objective of initiating a pivotal trial subsequent to 2011.
The Company is also leveraging the capabilities of its RNA-based technology platforms to develop therapeutics for the treatment of infectious diseases. The Company's RNA-based drug programs are clinically evaluated for the treatment of DMD and have also demonstrated anti-viral activity in infectious diseases such as Ebola, Marburg and H1N1 influenza in certain animal models. The Company's lead product candidates are at various stages of development.
Duchenne Muscular Dystrophy Program
The Company's lead program is designed to address specific gene mutations that result in DMD by forcing the genetic machinery to skip over an adjacent contiguous piece of RNA and, thus, restore the ability of the cell to express a new, truncated but functional, dystrophin protein.
Eteplirsen is an antisense PMO-based therapeutic in clinical development for the treatment of individuals with DMD who have an error in the gene codi! ng for dystrophin that can be treated by skipping exon 51. Eteplirsen targets the frequent series of mutations that cause DMD. Eteplirsen has been granted orphan drug designation in the United States and European Union. In addition to the Company's lead product candidate, eteplirsen, the Company is actively pursues development of a product candidate that skips exon 45 through an IND-enabling collaboration.
Anti-Viral Programs
The Company is implementing its RNA-based technology platforms in its anti-viral programs for the development of therapeutics to treat viruses, such as Ebola, Marburg and influenza. The Company's arrangement with DoD supporting the development of the Company's Ebola and Marburg virus drug candidates provides funding for all clinical and licensure activities necessary to obtain approval of a New Drug Application (NDA), by the United States Food and Drug Administration (FDA), if DoD exercises all of its options under the arrangement. During the year ended December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and is exploring funding opportunities or partnerships with DHHS and industry collaborators to advance its development.
The Company's anti-viral therapeutic programs use the Company's translation suppression technology and applies its PMOplus chemistry backbone, an advanced generation of its base PMO chemistry backbone that selectively introduces positive backbone charges to improve selective interaction between the drug and its target. The Company's translation suppressing technology is based on Translation Suppressing Oligomers (TSOs), which are PMO-based compounds that stop or suppress the translation of a specific protein by binding to their specific target sequence in mRNA.
The Company is pursuing development and regulatory approval of its Ebola and Marburg hemorrhagic fever virus product candidates under the FDA's Animal Rule. The Company's lead product candidate against the Ebola virus infec! tion is A! VI-6002. For Marburg virus infection, the Company's lead product candidate has been AVI-6003. In February 2012, the Company announced that the Company received approval from the FDA to remove one of the two oligomers composing AVI-6003 and proceed with a single oligomer approach, AVI-7288, given that efficacy in non-human primates has been demonstrated to be attributable to this single oligomer. The Company is exploring the feasibility of alternate routes of administration of its Ebola and Marburg drug candidates, and at DoD's invitation, the Company is developing a proposal to be submitted for a study to demonstrates feasibility of the intramuscular route.
AVI-6002, which is a combination of AVI-7537 and AVI-7539, is designed for post-exposure prophylaxis after documented or suspected exposure to the Ebola virus. The Company is evaluating the feasibility of developing AVI-7537 as a single agent for the post-exposure prophylaxis after documented or suspected exposure to Ebola virus. AVI-6003, which is a combination of AVI-7287 and AVI-7288, is designed for post-exposure prophylaxis after documented or suspected exposure to Marburg virus. In February 2012, the Company announced that the Company received approval from the FDA to proceed with AVI-7288 as a single agent against Marburg virus infection. The Company intends to proceed with dosing AVI-7288 in the Phase I multiple ascending dose studies and in non-human primate studies.
Influenza Program
The Company's anti-viral therapeutic programs are also focused on the development of the Company's product candidates designed to treat pandemic influenza viruses. AVI-7100 is the Company's lead product candidate for the treatment of influenza and employs its PMOplus technology. In June 2011, the Company initiated dosing of AVI-7100 through intravenous infusion in single-ascending doses in up to 48 healthy adult volunteers. As of December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and are exp! loring fu! nding opportunities or partnerships to advance its development.
The Company has developed three new phosphorodiamidate-linked morpholino oligomers (PMO)-based chemistry platforms in addition to its original PMO-based technology. The Company's PMO-based molecules are designed to sterically block the access of cellular machinery to pre-mRNA and mRNA without degrading the RNA. Through this selective targeting, two distinct biologic mechanisms of action can be initiated: modulation of pre-mRNA splicing and inhibition of mRNA translation.
The Company competes with GlaxoSmithKline plc, Toyama Chemical, Alnylam Pharmaceuticals, Inc., Tekmira Pharmaceuticals Corp., Isis Pharmaceuticals, Inc., Prosensa, and Santaris Pharma A/S.
Advisors' Opinion:- [By TheStreet Staff]
Sarepta Therapeutics (SRPT) will have another big year, with an accelerated approval filing mid-year for the Duchenne muscular dystrophy drug eteplirsen in the U.S. and a significant and lucrative ex-U.S. partnership for the company's exon-skipping drug technology platform.
Best Life Sciences Companies To Own For 2014: Digiland International Ltd (G77.SI)
Digiland International Limited engages in the promotion, marketing, sale, and distribution of electronic and information technology products in Singapore and Asia. It trades computers, computer peripherals, and related accessories; and provides technical and consultancy services in high technology products. The company is headquartered in Singapore.
No comments:
Post a Comment